ACTRN12607000218493
Recruiting
Phase 2
Phase II Study Evaluating Efficacy and Safety of Everolimus with Letrozole for Management of Advanced (unresectable or metastatic) Non Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Treatment
Dept of Medical Oncology, Royal Adelaide Hospital0 sites20 target enrollmentApril 20, 2007
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on Small Cell lung cancer
- Sponsor
- Dept of Medical Oncology, Royal Adelaide Hospital
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically or cytologically proven diagnosis of non\-small cell lung cancer of either gender. 2\. Age \> 18 years for males. Females should be post\-menopausal, which is defined as:• Prior oopherectomy, or • 12 month\-history of amenorrhoea, or • FSH (Follicle Stimulating Hormone) and LH (Luteinizing Hormone) in post\-menopausal range. There is no upper age limit. 3\. performance status \= 2\.4\. Adequate organ function• Hematological\- Hb\> 90 g/L, Absolute Neutrophil Count \= 1\.5 x 109/L, platelets \= 100 x 109/L.• Liver functions\- bilirubin \= 2 x upper limit normal (ULN), Aspartate Aminotransferase /Alanine Aminotransferase/ Alkaline Phosphatase \= 2\.5 x ULN or \= 5 x ULN in presence of liver metastases, S. albumin \= 30 g/L.• Renal function\- Creatinine \= 2 ULN, Creatinine clearance \> 30 mL/min. 6\. Patients should stop any hormonal medication as hormone replacement therapy or progesterone at least one month prior to enrolment. 7\. Patients should have at least one measurable lesion by RECIST criteria.
Exclusion Criteria
- •1\. Untreated brain metastases. 2\. Patients on strong inhibitor or inducer of isoenzyme CYP3A. 3\. Serious co\-morbidities such as severe cardiac failure or severe pulmonary compromise or severe and active infections. 4\. Uncontrolled diabetes.5\.Patients with grade 3 hypercholesterolemia / hypertriglyceridemia or \= grade 2 hypercholesterolemia / hypertriglyceridemia with history of coronary artery disease (despite lipid lowering treatment if given)6\. Previous treatment with mTOR inhibitors and/or known hypersensitivity to mTOR inhibitors.7\. A known history of Human Immunodeficiency Virus or previous seropositivity for the virus.8\. Leptomeningeal or uncontrolled brain metastases, including patients who continue to require glucocorticoids or intrathecal chemotherapy for brain or leptomeningeal metastases (documented by lumbar puncture).9\. Patients will be excluded if they are on raloxifene or tamoxifen. 10\. Patients who have an impairment of gastrointestinal function or who havegastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Evaluation of efficacy and safety of Ebola vaccine iEvac-Z in humaJPRN-jRCTs031190118Koga Michiko30
Completed
Not Applicable
A pilot study to evaluate safety and efficacy of electrohydraulic lithotripsy for difficult biliary and pancreatic stonesBiliary and pancreatic stonesJPRN-UMIN000013130Graduate School of Medicine, The University of Tokyo30
Completed
Not Applicable
Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myelomaMultiple MyelomaJPRN-UMIN000016265Sapporo Medical University Hospital30
Active, not recruiting
Phase 1
A trial to investigate the use of Veregen ointment in the treatment of vulval intraepithelial neoplasia, a severe skin disorder that may lead to vulval cancer.Vulval intraepithelial neoplasia (VIN)MedDRA version: 16.1Level: LLTClassification code 10057313Term: Vulval intraepithelial neoplasia grade IIISystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2013-003107-19-GBniversity of Birmingham26
Completed
Phase 2
Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)JPRN-UMIN000020773Translational Research Informatics Center, Foundation for Biomedical Research and Innovation39